RecruitMe Clinical Trial

Randomized, Double-Blind, Placebo Controlled, Multi-center Registration Trial To Evaluate The Efficacy and Safety of TTP488 In Patient With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine
A study for patients with Alzheimer's Disease using study drug azeliragon (TTP488)
Sponsor:vTv
Enrolling:Male and Female Patients
Age Range:Between 50 and 99 years old
IRB Number:AAAQ6252
U.S. Government ID:NCT02080364
Contact: Evelyn Dominguez-Rivera: 212-305-2371 / edd5@cumc.columbia.edu
Additional Study Information:

This study is for patients with Alzheimer's Disease. Alzheimers disease is a disorder characterized by progressive loss of memory, thinking, and behavior. An earlier study in patients having mild to moderate Alzheimers disease has demonstrated more pronounced benefit of treatment with azeliragon among participants with mild disease than among participants with moderate disease The purpose of this study is to learn how well azeliragon works and how safe study medication is compared to placebo in participants having mild Alzheimers disease. A placebo is an inactive material that looks like the study medication but does not contain any active study medication. Researchers use a placebo to see if the study medication works better or is safer than not taking anything.

This study is closed
Investigator
Lawrence Honig, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Evelyn Dominguez-Rivera
Email: edd5@cumc.columbia.edu
Phone: 212-305-2371